Post by
Noteable on Apr 21, 2023 3:15pm
Oncolytic Virus/vaccines present promising updates at AACR
April 21, 2023 - The burgeoning field of cancer vaccines enjoyed a moment in the spotlight this week as Modena, Merck, Transgene and Nykode all reported promising updates in combination with immune checkpoint inhibitors.
Moderna and Merck presented data from a Phase II trial comparing the safety and efficacy of their personalized cancer vaccine, mRNA-4157/V940. The vaccine led to a 44% reduction in recurrence or death.
While the data drew attention, concerns over the regulatory trajectory for the vaccine arose.
https://www.biospace.com/article/cancer-vaccines-steal-the-stage-at-aacr-nykode-transgene-moderna-and-merck-/
The pathway for Moderna and Merck likely doesn't include an accelerated approval, SVB Securities analyst Mani Foroohar said in a note to clients. He said accelerated approval is rare for adjuvant treatments — maintenance drugs intended for patients following surgery.
Comment by
Noteable on Apr 21, 2023 9:23pm
Promising presentations on OVs and vaccines at AACR seem to be a precursor for ONCY's positive data at a a major medical conference in the very near future.